SBF2 and esophageal squamous cell carcinoma: Functional experiments have shown that silencing SBF2‐AS1 upregulates cyclin-dependent kinase inhibitor 1A (CDKN1A) expression in ESCC, affceting cell cycle arrest and thereby restraining the proliferative ability of ESCC cells via arresting them at the G2 phase [32].